Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.34 |
| ▸ | SCN2B | O60939 | 1/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.33 |
| ▸ | CDK9 | P50750 | 2/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | GPR6 | P46095 | 3/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL830167 | 0.85 | EDNRB (0.42) | EDNRBTP53PTGDR2 | |
| SCHEMBL3693786 | 0.84 | EDNRB (0.38) | EDNRBTP53ROCK2PTGDR2 | |
| SCHEMBL8858776 | 0.84 | SCN9A (0.40) | EDNRBSCN9ASCN5ASCN2BSCN1A | |
| SCHEMBL831683 | 0.83 | CYP2C8 (0.38) | EDNRBSCN9ASCN5APPARGSCN2B | |
| SCHEMBL862647 | 0.81 | EDNRB (0.41) | EDNRBSCN9ASCN5APPARGSCN1A | |
| SCHEMBL831032 | 0.81 | PTGDR2 (0.36) | EDNRBSCN9ASCN5ASCN2BSCN1A | |
| SCHEMBL862295 | 0.80 | HDAC1 (0.34) | EDNRBSCN9ASCN5ASCN2BSCN1A | |
| SCHEMBL831766 | 0.78 | CYP2C8 (0.38) | EDNRBSCN9ASCN5ASCN2BSCN1A | |
| SCHEMBL829588 | 0.78 | PPARG (0.44) | EDNRBSCN9APPARGTP53PTGDR2 | |
| SCHEMBL14802288 | 0.78 | RXFP1 (0.36) | SCN9ASCN5ATP53GPR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | EDNRB 1094/4885SCN9A 3807/4885SCN5A 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.